BANYU RECEIVES JAPAN MANUFACTURING APPROVAL FOR FOSAMAX, TREATMENT DRUG FOR OSTEOPOROSIS

Banyu Pharmaceutical Co., Ltd. obtained manufacturing approval for Fosamax Plus D -- generic name: aledronate sodium. Fosamax was first launched in Japan in 2001 and since has proven to be an effective drug for patients of postmenopausal osteoporosis, indicating an efficiency reduction of cells that cause bone loss.

JCN Network (http://www.japancorp.net/Article.Asp?Art_ID=12966)